[Liver and artificial liver].
Despite good results of orthotopic liver transplantation in patients with fulminant hepatic failure the need still exists for an effective and safe artificial liver, able to temporarily take over the complex liver function so as to bridge the gap with transplantation or regeneration. Attempts to develop non-biological artificial livers have failed, mostly when controlled clinical trials were performed. In the last decade several different types of bioartificial livers have been devised, in which the biocomponent consists of freshly isolated porcine hepatocytes or a human hepatoblastoma cell line. The majority use semipermeable hollow fibers known from artificial kidney devices. The liver cells may lie either inside or outside the lumen of these fibers. In vitro analysis of liver function and animal experimental work showing that the bioartificial liver increases survival justify clinical application. Bioartificial livers are connected to patients extracorporeally by means of plasmapheresis circuit for periods of about 6 hours. In different trials about 40 patients with severe liver failure have been treated. No important adverse effects have not been reported in these phase I trials. Results of controlled studies are urgently needed. As long as no satisfactory immortalised human liver cell line with good function is available, porcine hepatocytes will remain the first choice, provided transmission of porcine pathogens to man is prevented.
Chamuleau
R A
RA
Afd. Maag-, Darm- en Leverziekten, Academisch Medisch Centrum/Universiteit van Amsterdam.
D000818:Animals; D001672:Biocompatible Materials; D002478:Cells, Cultured; D002986:Clinical Trials as Topic; D005112:Extracorporeal Circulation; D006801:Humans; D017093:Liver Failure / Q000276:immunology / Q000628:therapy*; D016031:Liver Transplantation / Q000276:immunology / Q000379:methods*; D019164:Liver, Artificial / Q000009:adverse effects; D010956:Plasmapheresis; D013552:Swine
D001672:Biocompatible Materials